ATE456380T1 - Hypoxie-induzierbares vegf plasmid für ischämische erkrankung - Google Patents
Hypoxie-induzierbares vegf plasmid für ischämische erkrankungInfo
- Publication number
- ATE456380T1 ATE456380T1 AT04713771T AT04713771T ATE456380T1 AT E456380 T1 ATE456380 T1 AT E456380T1 AT 04713771 T AT04713771 T AT 04713771T AT 04713771 T AT04713771 T AT 04713771T AT E456380 T1 ATE456380 T1 AT E456380T1
- Authority
- AT
- Austria
- Prior art keywords
- ischemic disease
- hypoxia
- vegf
- plasmids
- inducable
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 4
- 208000023589 ischemic disease Diseases 0.000 title abstract 4
- 239000013612 plasmid Substances 0.000 title abstract 4
- 206010021143 Hypoxia Diseases 0.000 title abstract 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 abstract 1
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44896103P | 2003-02-21 | 2003-02-21 | |
| PCT/US2004/005372 WO2004076633A2 (en) | 2003-02-21 | 2004-02-23 | Hypoxia inducible vegf plasmid for ischemic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE456380T1 true ATE456380T1 (de) | 2010-02-15 |
Family
ID=32927484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04713771T ATE456380T1 (de) | 2003-02-21 | 2004-02-23 | Hypoxie-induzierbares vegf plasmid für ischämische erkrankung |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7638322B2 (enExample) |
| EP (1) | EP1594549B1 (enExample) |
| JP (1) | JP4652325B2 (enExample) |
| KR (1) | KR101077689B1 (enExample) |
| AT (1) | ATE456380T1 (enExample) |
| CA (1) | CA2516727C (enExample) |
| DE (1) | DE602004025328D1 (enExample) |
| ES (1) | ES2339113T3 (enExample) |
| WO (1) | WO2004076633A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101094617B1 (ko) | 2004-08-16 | 2011-12-15 | 사일런스 테라퓨틱스 아게 | 알티피801 억제제의 치료적 용도 |
| DOP2007000015A (es) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | Usos terapéuticos de inhibidores de rtp801 |
| GB2450840B (en) * | 2006-05-11 | 2010-12-29 | Quark Pharmaceuticals Inc | Screening Systems Utilizing RTP801 |
| WO2007141796A2 (en) | 2006-06-09 | 2007-12-13 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of rtp801l |
| JP2010518880A (ja) | 2007-02-26 | 2010-06-03 | クアーク・ファーマスーティカルス、インコーポレイテッド | Ｒｔｐ８０１のインヒビター及びその疾患の治療における使用 |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030104973A1 (en) * | 1997-08-21 | 2003-06-05 | Quark Biotech, Inc. | Hypoxia-regulated genes |
| US6548633B1 (en) * | 1998-12-22 | 2003-04-15 | Genset, S.A. | Complementary DNA's encoding proteins with signal peptides |
-
2004
- 2004-02-23 WO PCT/US2004/005372 patent/WO2004076633A2/en not_active Ceased
- 2004-02-23 AT AT04713771T patent/ATE456380T1/de not_active IP Right Cessation
- 2004-02-23 KR KR1020057015480A patent/KR101077689B1/ko not_active Expired - Fee Related
- 2004-02-23 CA CA2516727A patent/CA2516727C/en not_active Expired - Fee Related
- 2004-02-23 EP EP04713771A patent/EP1594549B1/en not_active Expired - Lifetime
- 2004-02-23 ES ES04713771T patent/ES2339113T3/es not_active Expired - Lifetime
- 2004-02-23 US US10/546,115 patent/US7638322B2/en not_active Expired - Fee Related
- 2004-02-23 JP JP2006503825A patent/JP4652325B2/ja not_active Expired - Fee Related
- 2004-02-23 DE DE602004025328T patent/DE602004025328D1/de not_active Expired - Lifetime
-
2009
- 2009-12-29 US US12/649,141 patent/US7998941B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004076633A2 (en) | 2004-09-10 |
| DE602004025328D1 (de) | 2010-03-18 |
| US7638322B2 (en) | 2009-12-29 |
| KR20050103302A (ko) | 2005-10-28 |
| KR101077689B1 (ko) | 2011-10-27 |
| US20110015257A1 (en) | 2011-01-20 |
| JP2006518604A (ja) | 2006-08-17 |
| ES2339113T3 (es) | 2010-05-17 |
| JP4652325B2 (ja) | 2011-03-16 |
| US20070149467A1 (en) | 2007-06-28 |
| US7998941B2 (en) | 2011-08-16 |
| EP1594549A4 (en) | 2008-01-23 |
| CA2516727C (en) | 2014-02-04 |
| WO2004076633A3 (en) | 2005-06-02 |
| CA2516727A1 (en) | 2004-09-10 |
| EP1594549B1 (en) | 2010-01-27 |
| EP1594549A2 (en) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039985A1 (es) | Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima | |
| UY28396A1 (es) | Trompas de vegf y usos terapéuticos de las mismas | |
| MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
| TW200626138A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
| TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| CY1112948T1 (el) | Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζολιου, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους | |
| NO20060307L (no) | Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet | |
| CY1107051T1 (el) | Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους | |
| ATE332136T1 (de) | Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten | |
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| UA86400C2 (ru) | Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа | |
| ATE516366T1 (de) | Regulierte aptamer-therapeutika | |
| ATE543492T1 (de) | Behandlung von lungenkrebs | |
| NZ515891A (en) | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| ATE456380T1 (de) | Hypoxie-induzierbares vegf plasmid für ischämische erkrankung | |
| GEAP202516706A (en) | Cyclic peptides for trapping interleukin-1 beta | |
| NO20055692L (no) | Intravenos injeksjon av ikkeneurotoksiske plasminogenaktivatorer til behandling av cerebralt slag | |
| WO2004004664A3 (en) | Methods for treating or preventing ischemic injury | |
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| CA2356701A1 (en) | Gene therapy for diabetic ischemic disease | |
| Crossman et al. | Bradykinin induced wheal and flare is not mediated by histamine release or cyclooxygenase products. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |